JOP20200257A1 - تركيبات أوليجو نوكليوتيد وطرق لتحضيرها - Google Patents
تركيبات أوليجو نوكليوتيد وطرق لتحضيرهاInfo
- Publication number
- JOP20200257A1 JOP20200257A1 JOP/2020/0257A JOP20200257A JOP20200257A1 JO P20200257 A1 JOP20200257 A1 JO P20200257A1 JO P20200257 A JOP20200257 A JO P20200257A JO P20200257 A1 JOP20200257 A1 JO P20200257A1
- Authority
- JO
- Jordan
- Prior art keywords
- free
- linkage
- amino group
- solid phase
- dinucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
يتعلق الاختراع بتوفير طريقة ذات طور صلب لعمل أوليجو نوكليوتيدات من خلال دورات الإقران المتعاقب بما في ذلك خطوة إقران واحدة على الأقل لوحدة فرعية من داي نوكليوتيد دايمر بمجموعة طرفية 3’ حرة لسلسلة متنامية. تتضمن أوليجو نوكليوتيد وحدتين فرعيتين على الأقل من النوكليوزيد مرتبطة بواسطة رابط فوفسوراميدات N3? ?P5?. يمكن أن تتضمن الطريقة الخطوات (أ) نزع حماية مجموعة أمينية 3' تمت حمايتها للنوكليوزيد الطرفي المرتبط بمادة حاملة في الطور الصلب، تُشكل خطوة نزع مجموعة الحماية المذكورة مجموعة أمينية 3' حرة؛ (ب) تلامس المجموعة الأمينية 3' الحرة مع أمينو -داي نوكليوتيد- 5 - فوسفوراميديت دايمر تمت حمايته عند الطرف 3? في وجود محفز نوكليوتيد لتشكيل رابط نوكليوزيد N3? ?P5? فوسفوراميديت؛ و (ج) أكسدة الرابط (أي، المعالجة بالسلفر). يمكن أن تتضمن التركيبات المنتجة بواسطة الطرق المذكورة كمية قليلة من واحدة او أكثر (N-x) من منتجات أوليجو نوكليوتيد. يتم أيضاً توفير تركيبات صيدلية تتضمن تركيبات أوليجو نوكليوتيد التي يتعلق بها الاختراع.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461987396P | 2014-05-01 | 2014-05-01 | |
US201562151909P | 2015-04-23 | 2015-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20200257A1 true JOP20200257A1 (ar) | 2017-06-16 |
Family
ID=54359301
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2020/0257A JOP20200257A1 (ar) | 2014-05-01 | 2014-05-01 | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
JOP/2015/0089A JO3767B1 (ar) | 2014-05-01 | 2015-04-29 | تراكيب اوليغو نوكليوتيد و طرق تصنيعها |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2015/0089A JO3767B1 (ar) | 2014-05-01 | 2015-04-29 | تراكيب اوليغو نوكليوتيد و طرق تصنيعها |
Country Status (32)
Country | Link |
---|---|
US (4) | US9796747B2 (ar) |
EP (2) | EP4286519A3 (ar) |
JP (6) | JP7040892B2 (ar) |
KR (3) | KR20230088509A (ar) |
CN (3) | CN117357548A (ar) |
AP (1) | AP2016009489A0 (ar) |
AU (3) | AU2015253158B2 (ar) |
BR (1) | BR112016025196B1 (ar) |
CA (1) | CA2943888A1 (ar) |
CL (4) | CL2016002749A1 (ar) |
DK (1) | DK3137479T3 (ar) |
EA (1) | EA034882B9 (ar) |
ES (1) | ES2963740T3 (ar) |
FI (1) | FI3137479T3 (ar) |
HR (1) | HRP20231505T1 (ar) |
HU (1) | HUE064289T2 (ar) |
IL (2) | IL248044B (ar) |
JO (2) | JOP20200257A1 (ar) |
LT (1) | LT3137479T (ar) |
MX (2) | MX2016014178A (ar) |
MY (2) | MY178617A (ar) |
PE (1) | PE20170147A1 (ar) |
PH (1) | PH12016502080A1 (ar) |
PL (1) | PL3137479T3 (ar) |
PT (1) | PT3137479T (ar) |
RS (1) | RS64860B1 (ar) |
SG (2) | SG11201608226YA (ar) |
SI (1) | SI3137479T1 (ar) |
TW (2) | TWI712413B (ar) |
UA (1) | UA126108C2 (ar) |
WO (1) | WO2015168310A1 (ar) |
ZA (2) | ZA201606624B (ar) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100558739C (zh) * | 2004-07-02 | 2009-11-11 | 杰龙公司 | 合成被保护的3’-氨基核苷单体 |
JOP20200257A1 (ar) | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
US10745687B2 (en) | 2015-04-23 | 2020-08-18 | Geron Corporation | Methods of polynucleotide preparation using multivalent cation salt compositions |
DK3652187T3 (da) * | 2017-07-10 | 2021-12-13 | Geron Corp | Forbedret fremgangsmåde til fremstilling af imetelstat |
US11530179B2 (en) * | 2019-10-28 | 2022-12-20 | Geron Corporation | Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1 -(protected hydroxy)-propane salts and methods of making the same |
KR20220123300A (ko) | 2020-01-08 | 2022-09-06 | 닛토덴코 가부시키가이샤 | 분절-타입 아미디트(segment-type amidite)를 사용한 핵산 합성 방법 |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4046720A (en) | 1974-01-17 | 1977-09-06 | California Institute Of Technology | Crosslinked, porous, polyacrylate beads |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4413070A (en) | 1981-03-30 | 1983-11-01 | California Institute Of Technology | Polyacrolein microspheres |
US4678814A (en) | 1981-03-30 | 1987-07-07 | California Institute Of Technology | Polyacrolein microspheres |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US4757141A (en) | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
EP0462145B1 (en) | 1989-03-07 | 1994-04-27 | Genentech, Inc. | Covalent conjugates of lipid and oligonucleotide |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US6395492B1 (en) | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US6114513A (en) | 1990-01-11 | 2000-09-05 | Isis Pharmaceuticals, Inc. | Thiol-derivatized oligonucleotides |
AU7759291A (en) | 1990-03-29 | 1991-10-21 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
US5420330A (en) | 1990-09-07 | 1995-05-30 | Pharmacia P-L Biochemicals Inc. | Lipo-phosphoramidites |
US5419966A (en) | 1991-06-10 | 1995-05-30 | Microprobe Corporation | Solid support for synthesis of 3'-tailed oligonucleotides |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5837453A (en) | 1992-05-13 | 1998-11-17 | Geron Corporation | Telomerase activity assays |
US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
US7067497B2 (en) | 1992-09-29 | 2006-06-27 | Isis Pharmaceuticals, Inc. | Modulation of telomere length by oligonucleotides having a G-core sequence |
IL107150A0 (en) | 1992-09-29 | 1993-12-28 | Isis Pharmaceuticals Inc | Oligonucleotides having a conserved g4 core sequence |
US6087491A (en) | 1993-01-08 | 2000-07-11 | Hybridon, Inc. | Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
US6350853B1 (en) | 1993-04-26 | 2002-02-26 | Peter E. Nielsen | Conjugated peptide nucleic acids having enhanced cellular uptake |
DE4331670A1 (de) | 1993-09-17 | 1995-03-23 | Hoechst Ag | Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung |
EP1683863A3 (en) | 1993-10-18 | 2006-08-02 | The Walter And Eliza Hall Institute Of Medical Research | A method for enhancing neurone survival and agents useful for same |
US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
HUT76094A (en) | 1994-03-18 | 1997-06-30 | Lynx Therapeutics | Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties |
US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
US5726297A (en) | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
GB9413035D0 (en) | 1994-06-29 | 1994-08-17 | Scras | Antisense oligonucleeotides |
RO117328B1 (ro) | 1994-07-07 | 2002-01-30 | Geron Corp | Componenta rna a telomerazei de mamifere, plasmida recombinanta, de exprimare a acesteia, si metoda pentru detectarea prezentei unei stari neoplazice |
US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
EP0790965A1 (en) | 1994-11-07 | 1997-08-27 | HYBRIDON, Inc. | Synthesis of ?35 s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxide |
US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
US5840490A (en) | 1995-06-07 | 1998-11-24 | Mcmaster University | Telomerase activity associated with hematological and colorectal malignancies |
US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
US5859233A (en) | 1996-02-21 | 1999-01-12 | Lynx Therapeutics, Inc. | Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates |
GB9606158D0 (en) | 1996-03-23 | 1996-05-29 | Ciba Geigy Ag | Chemical compounds |
US6015710A (en) | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
WO1997037691A1 (en) * | 1996-04-10 | 1997-10-16 | Lynx Therapeutics, Inc. | Telomerase inhibitors |
US6111085A (en) | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
US6001991A (en) | 1996-10-04 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression |
AU733610B2 (en) | 1996-12-20 | 2001-05-17 | Geron Corporation | Methods for detecting and inhibiting the RNA component of telomerase |
US5846723A (en) | 1996-12-20 | 1998-12-08 | Geron Corporation | Methods for detecting the RNA component of telomerase |
US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
US5998604A (en) | 1997-09-15 | 1999-12-07 | The Perkin-Elmer Corporation | Polynucleotide purification method |
JP3722630B2 (ja) | 1998-10-28 | 2005-11-30 | パイオニア株式会社 | 記録再生装置 |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
CA2382521C (en) | 1999-09-10 | 2009-08-25 | Sergei Gryaznov | Oligonucleotide n3'.fwdarw.p5' thiophosphoramidates: their synthesis and use |
GB9927674D0 (en) * | 1999-11-23 | 2000-01-19 | Aegis Eng Ltd | Protective material |
US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
CA2440322C (en) | 2001-03-23 | 2014-09-09 | Geron Corporation | Oligonucleotide conjugates |
US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
US20120329858A1 (en) * | 2010-08-04 | 2012-12-27 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
BRPI0414222B8 (pt) | 2003-09-09 | 2021-05-25 | Geron Corp | compostos oligonucleotídeos modificados para inibição da telomerase, métodos, composição farmacêutica e usos relacionados |
CN100558739C (zh) | 2004-07-02 | 2009-11-11 | 杰龙公司 | 合成被保护的3’-氨基核苷单体 |
US7427675B2 (en) * | 2004-08-23 | 2008-09-23 | Isis Pharmaceuticals, Inc. | Compounds and methods for the characterization of oligonucleotides |
CA2584984A1 (en) * | 2004-10-18 | 2006-04-27 | Codon Devices, Inc. | Methods for assembly of high fidelity synthetic polynucleotides |
US7998938B2 (en) | 2005-04-15 | 2011-08-16 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
US8153604B2 (en) | 2006-04-24 | 2012-04-10 | Geron Corporation | CNS-tumor treatment method and composition |
SI2898887T1 (sl) | 2006-10-30 | 2019-01-31 | Geron Corporation | Kombinirani telomerazni inhibitor in gemcitabin za zdravljenje raka |
WO2008094640A2 (en) | 2007-01-30 | 2008-08-07 | Geron Corporation | Compounds having anti-adhesive effects on cancer cells |
US9106103B2 (en) | 2011-09-23 | 2015-08-11 | Eaton Corporation | Unintteruptible power supply systems and methods employing on-demand energy storage |
US9006630B2 (en) | 2012-01-13 | 2015-04-14 | Altasens, Inc. | Quality of optically black reference pixels in CMOS iSoCs |
US20150342982A1 (en) | 2012-12-07 | 2015-12-03 | Geron Corporation | Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms |
US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
JOP20200257A1 (ar) * | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
-
2014
- 2014-05-01 JO JOP/2020/0257A patent/JOP20200257A1/ar unknown
-
2015
- 2015-04-29 UA UAA201610381A patent/UA126108C2/uk unknown
- 2015-04-29 HR HRP20231505TT patent/HRP20231505T1/hr unknown
- 2015-04-29 EP EP23193452.2A patent/EP4286519A3/en active Pending
- 2015-04-29 SG SG11201608226YA patent/SG11201608226YA/en unknown
- 2015-04-29 MX MX2016014178A patent/MX2016014178A/es unknown
- 2015-04-29 SG SG10201911086XA patent/SG10201911086XA/en unknown
- 2015-04-29 DK DK15785822.6T patent/DK3137479T3/da active
- 2015-04-29 CN CN202311295220.7A patent/CN117357548A/zh active Pending
- 2015-04-29 MY MYPI2016703971A patent/MY178617A/en unknown
- 2015-04-29 CN CN202010050944.5A patent/CN111228288B/zh active Active
- 2015-04-29 US US14/699,902 patent/US9796747B2/en active Active
- 2015-04-29 KR KR1020237018801A patent/KR20230088509A/ko not_active Application Discontinuation
- 2015-04-29 WO PCT/US2015/028327 patent/WO2015168310A1/en active Application Filing
- 2015-04-29 EP EP15785822.6A patent/EP3137479B1/en active Active
- 2015-04-29 TW TW108147051A patent/TWI712413B/zh active
- 2015-04-29 TW TW104113709A patent/TWI709406B/zh active
- 2015-04-29 KR KR1020167029996A patent/KR102316282B1/ko active IP Right Grant
- 2015-04-29 EA EA201691786A patent/EA034882B9/ru unknown
- 2015-04-29 CA CA2943888A patent/CA2943888A1/en active Pending
- 2015-04-29 KR KR1020217033531A patent/KR20210130822A/ko not_active IP Right Cessation
- 2015-04-29 AU AU2015253158A patent/AU2015253158B2/en active Active
- 2015-04-29 CN CN201580022353.4A patent/CN106459134B/zh active Active
- 2015-04-29 BR BR112016025196-2A patent/BR112016025196B1/pt active IP Right Grant
- 2015-04-29 FI FIEP15785822.6T patent/FI3137479T3/fi active
- 2015-04-29 HU HUE15785822A patent/HUE064289T2/hu unknown
- 2015-04-29 PT PT157858226T patent/PT3137479T/pt unknown
- 2015-04-29 RS RS20231110A patent/RS64860B1/sr unknown
- 2015-04-29 JO JOP/2015/0089A patent/JO3767B1/ar active
- 2015-04-29 LT LTEPPCT/US2015/028327T patent/LT3137479T/lt unknown
- 2015-04-29 MY MYPI2020002421A patent/MY196927A/en unknown
- 2015-04-29 PL PL15785822.6T patent/PL3137479T3/pl unknown
- 2015-04-29 ES ES15785822T patent/ES2963740T3/es active Active
- 2015-04-29 PE PE2016002150A patent/PE20170147A1/es unknown
- 2015-04-29 AP AP2016009489A patent/AP2016009489A0/en unknown
- 2015-04-29 JP JP2016564990A patent/JP7040892B2/ja active Active
- 2015-04-29 SI SI201531963T patent/SI3137479T1/sl unknown
-
2016
- 2016-09-23 ZA ZA2016/06624A patent/ZA201606624B/en unknown
- 2016-09-26 IL IL248044A patent/IL248044B/en active IP Right Grant
- 2016-10-19 PH PH12016502080A patent/PH12016502080A1/en unknown
- 2016-10-28 MX MX2021004932A patent/MX2021004932A/es unknown
- 2016-10-28 CL CL2016002749A patent/CL2016002749A1/es unknown
-
2017
- 2017-09-14 US US15/705,021 patent/US11299511B2/en active Active
- 2017-09-14 US US15/705,019 patent/US10392418B2/en active Active
-
2018
- 2018-05-01 JP JP2018088277A patent/JP2018131453A/ja active Pending
- 2018-05-04 CL CL2018001213A patent/CL2018001213A1/es unknown
- 2018-05-04 CL CL2018001212A patent/CL2018001212A1/es unknown
-
2019
- 2019-08-07 IL IL268570A patent/IL268570B/en unknown
- 2019-12-25 JP JP2019234301A patent/JP2020050670A/ja not_active Withdrawn
-
2020
- 2020-03-06 AU AU2020201707A patent/AU2020201707B2/en active Active
- 2020-09-22 ZA ZA2020/05857A patent/ZA202005857B/en unknown
-
2021
- 2021-09-06 JP JP2021144677A patent/JP2021182946A/ja active Pending
-
2022
- 2022-01-18 JP JP2022005584A patent/JP7308309B2/ja active Active
- 2022-01-26 CL CL2022000202A patent/CL2022000202A1/es unknown
- 2022-03-16 US US17/696,300 patent/US11739114B2/en active Active
- 2022-05-16 AU AU2022203273A patent/AU2022203273A1/en not_active Abandoned
-
2023
- 2023-04-03 JP JP2023060170A patent/JP2023073510A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016502080A1 (en) | Oligonucleotide compositions and methods of making the same | |
CY1124632T1 (el) | Προϊοντα συζευξης αναλογων cc-1065 και διλειτουργικοι συνδετες | |
PH12018500145A1 (en) | Oligonucleotide compositions and methods thereof | |
BR112017016681A2 (pt) | vetor de coexpressão de vacina e moléculas coestimulatórias | |
WO2016160844A3 (en) | Methods and compositions for combinatorial barcoding | |
NZ631512A (en) | Compositions and methods for modulating apolipoprotein (a) expression | |
MX2019012223A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
EA201690274A1 (ru) | Способ сайт-специфического ферментативного мечения нуклеиновых кислот in vitro введением не встречающихся в природе нуклеотидов | |
MX2016009290A (es) | Diseño quiral. | |
MX2020001158A (es) | Composiciones nucleotidicas modificadas con citidina-5-carboxamida y metodos relacionados con las mismas. | |
NZ630591A (en) | Microrna compounds and methods for modulating mir-21 activity | |
WO2015066638A3 (en) | Optimal maize loci | |
WO2014172489A3 (en) | Targeted modification of rat genome | |
UA118014C2 (uk) | Спосіб модифікації днк-мішені | |
BR112014009066B8 (pt) | molécula de ácido nucleico, método para a sintetização de uma molécula de dna de triciclo-fosforotioato e composição farmacêutica | |
WO2011160052A3 (en) | Methods and compositions for sequence specific rna endonucleases | |
MX2022003952A (es) | Conjugados de biomoleculas. | |
WO2022084331A3 (en) | Novel ligands for asialoglycoprotein receptor | |
WO2012082753A3 (en) | Polymerization of nucleic acids using activation by polyphosphorolysis (app) reactions | |
EA202090282A1 (ru) | Композиции олигонуклеотидов и способы их получения | |
AR100235A1 (es) | Composiciones de oligonucleótidos y métodos para realizarlas | |
TH166778A (th) | องค์ประกอบโอลิโกนิวคลีโอไทด์และวิธีการในการทำองค์ประกอบนี้ | |
AR105066A1 (es) | Enzimas y sistemas crispr | |
UA54336U (ru) | Способ выявления рнк вируса геморрагической септицемии форели при помощи обратно - транскриптазной полимеразной цепной реакции | |
RU2013106976A (ru) | Набор синтетических олигонуклеотидов для амплификации и секвенирования its1-5.8s-its2 сосудистых растений |